期刊文献+

前列腺癌中netrin-1/UNC5B的表达及临床意义 被引量:1

Expressions of netrin-1 and UNC5B in prostate cancer and their clinical significance
下载PDF
导出
摘要 目的:通过比较不同侵袭能力的前列腺癌细胞netrin-1/UNC5B表达量的差异,为前列腺癌寻找新的生物标志物及治疗手段。方法:选取前列腺癌细胞系DU145、22RV1、PC3、PC3M、RWPE-1,通过RT-PCR、Western印迹检测netrin-1/UNC5B的表达及其差异,并通过免疫荧光检测配体netrin-1及其受体UNC5B在前列腺癌细胞中的定位。结果:netrin-1/UNC5B在前列腺癌细胞中均表达,侵袭能力强的前列腺癌细胞中netrin-1表达量明显增多(P<0.05),而UNC5B在RWPE-1(正常细胞)中表达量明显增多(P<0.05)。结论:netrin-1/UNC5B表达量与前列腺癌的浸润及进展程度紧密关联,有望作为一种潜在的生物标志物来预测前列腺癌的恶性程度。 Objective: To search for a new diagnostic biomarker for prostate cancer by comparing the differences in the expres- sions of netrin-1 and UNCSB in prostate cancer cells with different invasive abilities. Methods: We examined the expressions of ne- trin-1 and UNCSB in five prostate cancer cell lines DU145, 22RV1, PC3, PC3M and RWPE-1 using RT-PCR and Western blot, and positioned the ligands netrin-1 and its receptor UNCSB in the prostate cancer cells by immunoflaorescence. Results: Both netfin-1 and UNCSB were expressed in the prostate cancer cells, and the expression of netrin-1 was significantly increased in highly invasive cells (P 〈 0.05 ), while that of UNCSB in RWPE-1 (normal) cells ( P 〈 0.05 ). Conclusion : The expressions of netfin-1 and UNCSB are closely related to the infiltration and progression of prostate cancer, and expected to be as potential biomarkers for predic- ting the malignancy degree of prostate cancer.
作者 刘娇 孔垂泽
出处 《中华男科学杂志》 CAS CSCD 2013年第12期1072-1076,共5页 National Journal of Andrology
关键词 前列腺癌 NETRIN-1 UNC5B DU145细胞 22RV1细胞 PC3细胞 PC3M细胞 RWPE-1细胞 prostate cancer netrin-1 UNC5B DU145 cell 22RV1 cell PC3 cell PC3M cell RWPE-1 cell
  • 相关文献

参考文献2

二级参考文献28

  • 1张世革,王益华,丁毅,吴烨.晚期前列腺癌联合雄激素阻断治疗的长期随访[J].中华男科学杂志,2005,11(10):770-771. 被引量:2
  • 2Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostare cancer[J]. N Engl J Med, 2004, 351(15) :1488-1490.
  • 3Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer[ J ].Eur Urol, 2001, 39(2) :121-130.
  • 4Chen CD, Welsbie D, Tran C, et al. Molecular determinants of resistance to antiandregen therapy[J]. Nat Med, 2004, 10( 1 ) :33-39.
  • 5Hasumi H, Ishiguro H, Nakamura M, et al. Neuroserpin (PI-12 ) is upregulated in high-grade prostate cancer and is associated with survival[J]. Int J Cancer, 2005, 115(6) : 911-916.
  • 6Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractary disease [ J ]. Endocr Relat Cancer, 2005, 12(1): 109-117.
  • 7Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J]. N Engl J Med, 2004, 351( 15 ) : 1513-1520.
  • 8Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351(15) :1502-1512.
  • 9Abratt RP, Brune D, Dimopoulos MA, et al. Randomised phase Ⅲ study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer[ J ].Ann Oncol, 2004, 15(11) : 1613-1621.
  • 10Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after firstline epothilone-B analog ixabepilone ( BMS-247550 ) therapy [ J ].Cancer, 2006, 106( 1 ) :58-62.

共引文献18

同被引文献14

  • 1Gonzalez E, Piva M, Rodriguez-Suarez E, et al. Human mammospheres secrete hormone-regulated active extracell EJ]. PLoS One, 2014, 9(1) : e83955, doi: 10. 1371/ journal, pone. 0083955.
  • 2eCollection 2014. Laumonnerie C, Da Silva RV, Kania A, et al. Netrinl and Dcc signalling are required for confinement of central axons within the central nervous system [ J 1. Develop- ment, 2014, 141(3):5944503.
  • 3Mavrova R, Rodasa J, Schmitt K, et al. Estrogen, pro- gesterone, and Her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer[J].Breast J, 2014, 20(3) : 322-324.
  • 4Pollock J, Welsh JS. Clinical cancer genetics. Part 2: Breast[J]. AM J Clin Oncol, 2014, 37(1) : 86-89.
  • 5Paoletti C, Hayes DF. Molecular testing in breast cancer [J]. Annu Rev Med, 2014, 65: 95-110.
  • 6Gilbert K, Figueredo S, Meng XY, et al. Serum protein- expression profiling using the Protein Chip biomarker sys- tem[J].Methods Mol Biol, 2004, 264 : 259-269.
  • 7Delloye-Bourgeois C, Brambilla E, Coissieux MM, et al. Interference with Netrin-1 and tumor cell death in non- small cell lung cancer[J].J Natl Cancer Inst, 2009, 101 (4) : 237-247.
  • 8Papanastasiou AD, Pampalakis G, Katsaros D, et al. Netrin-1 overexpression is predictive of ovarian malig- nancies[J]. Oncotarget, 2011, 2(5): 363-367.
  • 9Liu J, Kong CZ, Gong DX, et al. Pkc alpha regulates netrin-1/unc5b-mediated survival pathway in bladder cancer[J].BMC Cancer, 2014,14:93. doi: 10. 1186/ 1471-2407-14-93.
  • 10Bernet A, Fitamant J. Netrin-1 and its receptors in tumour growth promotion[J].Expert Opin Ther Tar- gets, 2008, 12(8): 995-1007.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部